Sangamo BioSciences, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryPharmaceuticals and Healthcare
Key Findings
Pharmaceuticals and Healthcare
Pharmaceuticals and Healthcare
Reasons To Buys
MarketLine
Key Highlights
United States
Sangamo BioSciences is a clinical stage biotechnology company focused on translating science into genomic medicines using its platform technologies in gene therapy and in vivo genome regulation. The company is focused on these therapeutic areas: inherited metabolic diseases, central nervous system diseases and inflammatory and autoimmune diseases. The company is evaluating its wholly-owned investigational ST-920 gene therapy for Fabry disease, an inherited metabolic disease. Under its agreement with Sanofi Genzyme, the company is developing ST-400 and BIVV-003, ex vivo gene-edited cell therapies, for hemoglobinopathies including transfusion dependent beta thalassemia and sickle cell disease.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.